VP, DMD Commercial Asset Lead

Company Overview

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.

The VP, DMD Commercial Asset Lead (CAL) is a passionate driver for maximizing the value of Dyne’s DMD commercial assets with a global perspective. The CAL brings adaptable leadership to develop and implement commercialization strategies to maximize the reach and value creation of Dyne’s DMD commercial assets in the neuro‑muscular portfolio.

• Define global asset commercialization strategy and plan to achieve milestones and timelines for successful launches
• As a key member of the Program Team and Head of DMD Commercial Sub Team, ensure that all key pillars for successful commercialization for the assets are secured – starting with differentiation in endpoints to achieve a competitive product profile/label, regulatory strategy, filing strategy, with value & access to secure the value proposition for the assets and achieve reimbursement in US and at the right time globally, partner with supply, medical, marketing, digital and the data team to prepare successful launch strategy and execution for all key markets starting with US.
• Provide input and expertise to a robust and well-understood program strategy with the key objective of gaining the approval of potentially life‑changing medicines for patients around the world to generate value for patients and shareholders and maximize to line growth.
• Structure and facilitate critical cross‑functional decisions on commercialization aspects of the asset within Program Teams and senior leadership teams, bringing all relevant perspectives to bear while driving to efficient decisions in a fast‑paced environment.
• Working with cross‑functional all launch team in key markets, starting with the US team, and Strategic Commercialization Partners to secure reimbursement and successful launches, by propelling successful launch execution from one country to the other.
• In close collaboration with the Program Lead and Head of Commercialization, consider and advocate for the needs of the commercial asset in the context of Dyne’s corporate strategy and priorities.
• Drive preparation and presentation of materials for Board of Directors on asset commercialization topics.
• Maintain clear, open, and proactive communication with the senior leadership team and other stakeholders regarding commercialization strategy, status, priorities, risks and needs, and facilitate appropriate decision‑making.
• Keep abreast of competitor landscape and development in the fields of muscle diseases and oligonucleotide drug discovery and development.
• Build visible, constructive, and credible presence within the DMD community including with KOLs, the holistic teams engaged in patient care and patient community.
• Participate in business development activities, as needed, including opportunity evaluations and due diligence.
• Provide a motivating leadership example within Dyne more broadly during periods of rapid growth.
• Foster a culture of collaboration, innovation, discovery, and cutting‑edge research.
• Focused on scientific excellence, open communication, and continuous improvement.
• Role model Dyne’s core values.

• Bachelor’s degree in a relevant scientific, medical, or business discipline required; advanced degree (MD, PhD, Pharm
  
  D, MBA, or Master’s in Life Sciences) strongly preferred.
• Minimum of 20 years of experience in the biopharmaceutical industry.
• 15+ years of commercialization and cross‑functional leadership experience within the biopharmaceutical industry, including substantial involvement in clinical development strategy, regulatory interactions, filing…